Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
about
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levelsAdenosine A2A receptors modulate acute injury and neuroinflammation in brain ischemiaOstracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature reviewProof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia.The Chemistry of Neurodegeneration: Kinetic Data and Their Implications.Effect of Caffeine Chronically Consumed During Pregnancy on Adenosine A1 and A2A Receptors Signaling in Both Maternal and Fetal Heart from Wistar RatsBinding of the Antagonist Caffeine to the Human Adenosine Receptor hA2AR in Nearly Physiological ConditionsMedicinal chemistry of adenosine, P2Y and P2X receptors.Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma.Purinergic receptors as potential therapeutic targets in Alzheimer's disease.Caffeine intake has no effect on sleep quality in community dwellers living in a rural Ecuadorian village (The Atahualpa Project).The safety of istradefylline for the treatment of Parkinson's disease.Modulation of excitatory neurotransmission by neuronal/glial signalling molecules: interplay between purinergic and glutamatergic systems.History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Rational drug discovery design approaches for treating Parkinson's disease.Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease.Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration.Health benefits of methylxanthines in neurodegenerative diseases.Quinazoline-based tricyclic compounds that regulate programmed cell death, induce neuronal differentiation, and are curative in animal models for excitotoxicity and hereditary brain diseaseHaving a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases.Endogenous adenosine release is involved in the control of heart rate in rats.The Zinc Finger Transcription Factor Sp9 Is Required for the Development of Striatopallidal Projection Neurons.Adenosine-mediated modulation of ventral horn interneurons and spinal motoneurons in neonatal mice.Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease.Behavioral and pathophysiological outcomes associated with caffeine consumption and repetitive mild traumatic brain injury (RmTBI) in adolescent rats.The Complexity of H-wave Amplitude Fluctuations and Their Bilateral Cross-Covariance Are Modified According to the Previous Fitness History of Young Subjects under Track Training.Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics.Caffeine Prevents Blood Retinal Barrier Damage in a Model, In Vitro, of Diabetic Macular Edema.Antidepressive-like effects and antioxidant activity of green tea and GABA green tea in a mouse model of post-stroke depression.Acute hyperammonemia and systemic inflammation is associated with increased extracellular brain adenosine in rats: a biosensor study.Biochemical and Pharmacological Role of A1 Adenosine Receptors and Their Modulation as Novel Therapeutic Strategy.A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo.Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders.Discovery of the first A1 adenosine receptor ligand based on the chromone scaffold
P2860
Q26751302-8F0FF9E3-E027-49EE-B993-3B780CFA722EQ26851322-801B21C5-E19F-48A7-9D97-FE693E529D96Q28243209-0C9C8DE6-5098-421E-BD14-CCF895A9A25DQ30426397-7A90CDC5-41B9-4107-900A-5AEF7E69AA98Q30973484-AA76AF28-4562-4D1C-9789-C8388E5B696BQ34709509-CC015926-948C-4397-AE75-45640C26495BQ35636233-9CEFF0CB-56C9-4775-BD86-13027AFF5F1EQ35873582-EEEEA60D-948E-4879-BAE6-60E9BC177506Q36043139-55081E52-C66B-485A-813E-02BCAFF65FD2Q36844881-9AC8CC85-74E3-4498-859A-75D6A164392FQ36901148-003CD095-4BA9-4898-9342-870E7E901158Q38353204-9DD915D4-9D85-4067-A80E-F2973CBDFE89Q38358456-7A94C46F-E404-4DFE-96C2-3E99CAE65246Q38395423-5564823B-E12B-4620-91B7-334A93349BD6Q38520864-9E53C1CD-857F-48E5-8CDD-9104ABCD07C0Q38658203-657F8D33-7739-4981-8B4D-0EAB51760D61Q38691042-24971583-E14F-423B-BE32-7C2B8EF01C31Q38772021-6B2E2E35-863C-4668-856D-22A7DDDFFB07Q38924439-7EEC158E-ABCB-4C6C-872B-0229C144AA1BQ39157059-028068FC-F8AA-42C5-8D1D-4C3A22AA8520Q40682600-059F8042-DCE6-4777-9609-67DBD6CAEB57Q41905585-56534ABF-C999-4F41-AF24-7BE456F3C173Q41947828-FEB25591-BA69-4E7F-9D5E-3B4813ADCBA8Q42230705-51372A8B-6AAE-4AC3-852E-C5B8CD371BF4Q47099714-2EB14DD3-0C29-43D9-AAAC-04DD9E172CD1Q47116434-70FEDE61-377B-41E6-899A-66F0857DF66FQ47225761-06CDACB0-079D-40D8-98A7-9190DD78D543Q47993545-4F9D4321-3EC6-48D9-A14B-ABD2949A324EQ48069397-CA37B846-AF08-4F07-85D7-F12FEA3FF7C7Q48718041-91BA560C-733E-4664-91C3-AC1BF3747CA5Q48732639-ED304E90-B02C-4D9B-A55A-592AF06569F7Q49452726-0E4AE74A-5708-4035-9190-8C52D9C9526CQ55360003-28C3DC9C-51E9-49A7-8534-4B8521C9578FQ56990809-98524FDF-D472-44BE-84E9-FF2818D08B7F
P2860
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Using caffeine and other adeno ...... generative diseases: a review.
@ast
Using caffeine and other adeno ...... generative diseases: a review.
@en
type
label
Using caffeine and other adeno ...... generative diseases: a review.
@ast
Using caffeine and other adeno ...... generative diseases: a review.
@en
prefLabel
Using caffeine and other adeno ...... generative diseases: a review.
@ast
Using caffeine and other adeno ...... generative diseases: a review.
@en
P2860
P1433
P1476
Using caffeine and other adeno ...... egenerative diseases: a review
@en
P2093
Marla Rivera-Oliver
P2860
P356
10.1016/J.LFS.2014.01.083
P407
P577
2014-02-13T00:00:00Z